K. Longenecker

发表

Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.

S. C. Panchal, Philip B. Cox, P. Hajduk, 2020, Journal of medicinal chemistry.

Structure of MurF from Streptococcus pneumoniae co‐crystallized with a small molecule inhibitor exhibits interdomain closure

P. Hajduk, K. Longenecker, V. Stoll, 2005, Protein Science.

Structure‐based Optimization of MurF Inhibitors

David D. Anderson, P. Hajduk, K. Longenecker, 2006, Chemical biology & drug design.

Protein crystallization by rational mutagenesis of surface residues: Lys to Ala mutations promote crystallization of RhoGDI.

K. Longenecker, Z. Derewenda, P. Sheffield, 2001, Acta crystallographica. Section D, Biological crystallography.

Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.

K. Longenecker, Jyoti R. Patel, H. Sham, 2007, Bioorganic & medicinal chemistry letters.

Structure of the BH Domain from Graf and Its Implications for Rho GTPase Recognition*

K. Longenecker, J. Parsons, Z. Dauter, 2000, The Journal of Biological Chemistry.

Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

K. Longenecker, A. C. Krueger, A. Molla, 2013, Bioorganic & medicinal chemistry letters.

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.

G. L. Hamilton, K. Longenecker, H. Sham, 2007, Bioorganic & medicinal chemistry letters.

Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition.

K. Longenecker, P. Roach, T. Hurley, 1996, Journal of molecular biology.

Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors.

K. Longenecker, H. Sham, K. Stewart, 2006, Bioorganic & medicinal chemistry letters.

From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish

K. Longenecker, R. Peterson, S. Fossey, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

On-column ligand exchange for structure-based drug design: a case study with human 11β-hydroxysteroid dehydrogenase type 1.

K. Longenecker, R. Judge, J. Harlan, 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

Three‐dimensional structure, binding, and spectroscopic characteristics of the monoclonal antibody 43.1 directed to the carboxyphenyl moiety of fluorescein

K. Longenecker, R. Judge, K. Swift, 2016, Biopolymers.

Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain.

K. Longenecker, P. Kovar, L. Hasvold, 2020, Journal of medicinal chemistry.

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.

K. Longenecker, J. Segreti, H. Sham, 2006, Journal of medicinal chemistry.

Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors

K. Longenecker, R. Judge, Deanne F. Stolarik, 2007 .

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

C. Tse, K. Longenecker, P. Richardson, 2017, Molecular Cancer Therapeutics.

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Ana L. Aguirre, Mikkel A. Algire, C. Tse, 2017, Bioorganic & medicinal chemistry letters.

Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.

K. Longenecker, H. Sham, Xiaofen Li, 2007, Journal of medicinal chemistry.

The Effect of Ionic Liquids on Protein Crystallization and X-ray Diffraction Resolution

K. Longenecker, M. Chiu, C. Abad-Zapatero, 2009 .

Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

K. Longenecker, H. Sham, R. Fryer, 2006, Journal of medicinal chemistry.

Structure of a constitutively activated RhoA mutant (Q63L) at 1.55 A resolution.

K. Longenecker, Z. Derewenda, R. Nakamoto, 2003, Acta crystallographica. Section D, Biological crystallography.

Expression, purification, and crystallization of the RGS-like domain from the Rho nucleotide exchange factor, PDZ-RhoGEF, using the surface entropy reduction approach.

M. E. Lewis, K. Longenecker, Z. Derewenda, 2001, Protein expression and purification.

Structure of the RGS-like domain from PDZ-RhoGEF: linking heterotrimeric g protein-coupled signaling to Rho GTPases.

M. E. Lewis, K. Longenecker, Z. Derewenda, 2001, Structure.

Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5

K. Longenecker, Chaohong Sun, D. Kempf, 2017, Acta crystallographica. Section F, Structural biology communications.

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.

Vincent S Stoll, K. Longenecker, V. Stoll, 2006, Biochemistry.

The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.

Ryan A McClure, K. Longenecker, Chaohong Sun, 2022, ACS chemical biology.

Crystal structure and thermodynamic analysis of diagnostic mAb 106.3 complexed with BNP 5‐13 (C10A)

K. Longenecker, P. Richardson, Q. Ruan, 2009, Proteins.

Recombinant rabbit muscle casein kinase I α is inhibited by heparin and activated by polylysine

K. Longenecker, P. Graves, A. Depaoli-Roach, 1992 .

Crystallographic studies of casein kinase I delta toward a structural understanding of auto-inhibition.

K. Longenecker, P. Roach, T. Hurley, 1998, Acta crystallographica. Section D, Biological crystallography.

Human RhoA/RhoGDI complex expressed in yeast: Gtp exchange is sufficient for translocation of RhoA to liposomes

K. Longenecker, Xiaopu Liu, R. Nakamoto, 2008, Protein science : a publication of the Protein Society.

How RhoGDI binds Rho.

K. Longenecker, Z. Dauter, Z. Derewenda, 1999, Acta crystallographica. Section D, Biological crystallography.

Cysteinylation of a monoclonal antibody leads to its inactivation

K. Longenecker, J. Fishpaugh, C. Ramsay, 2016, mAbs.

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.

K. Glaser, L. Lam, C. Tse, 2017, Biochemical and biophysical research communications.

Complex of human Melanotransferrin and SC57.32 Fab fragment reveals novel interdomain arrangement with ferric N-lobe and open C-lobe

K. Longenecker, V. Stoll, S. Vivona, 2021, Scientific reports.

Complex of human Melanotransferrin and SC57.32 Fab fragment reveals novel interdomain arrangement with ferric N-lobe and open C-lobe

K. Longenecker, V. Stoll, S. Vivona, 2021, Scientific Reports.

The impact of Glu-->Ala and Glu-->Asp mutations on the crystallization properties of RhoGDI: the structure of RhoGDI at 1.3 A resolution.

K. Longenecker, J. Otlewski, Z. Dauter, 2002, Acta crystallographica. Section D, Biological crystallography.

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability.

K. Longenecker, A. C. Krueger, A. Molla, 2018, Journal of medicinal chemistry.

Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity.

K. Longenecker, V. Stoll, S. Vivona, 2020, Journal of structural biology.

Mechanism of putrescine transport in human pulmonary artery endothelial cells.

K. Longenecker, W. Martin, D. Kachel, 1993, Journal of Pharmacology and Experimental Therapeutics.

Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.

K. Longenecker, T. Penning, Y. Tong, 2021, ACS medicinal chemistry letters.

Fragment-based discovery of a potent NAMPT inhibitor.

K. Longenecker, A. Petros, R. Clark, 2017, Bioorganic & medicinal chemistry letters.

Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.

K. Longenecker, R. Judge, Deanne F. Stolarik, 2007, Bioorganic & medicinal chemistry letters.

An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases

K. Longenecker, A. Hobson, S. Mathieu, 2024, Science Translational Medicine.